More than half of labs are reporting they're running short on test kits, pipettes and crucial chemicals.

One of the two leading vaccine candidates requires deep, deep freezing. Here's how communities are working to solve for this and how the new Moderna vaccine could help.

The vaccine is nearly 95% effective in preventing illness, according to an interim analysis of a clinical test involving 30,000 people.

The $1.6 billion Novavax contract is one of several Operation Warp Speed agreements issued through a third party, Advanced Technology International, and that hadn't been released.

Eli Lilly's monoclonal antibody will be available to people 65 or older or those with underlying health conditions. Supplies will be short, and allocating the medicine will be a challenge.

The pandemic is once again putting tens of thousands of people in the hospital in the U.S. Is it more than the health care system can handle? Find out which states are getting close to their limit.

Katherine Standefer was uninsured and working as a hiking guide when diagnosed with a genetic heart condition. She chronicles her experience with an implanted heart device in Lightning Flowers.

Pfizer's COVID-19 vaccine is the first to have data showing that it exceeded the minimum effectiveness threshold set by the Food and Drug Administration for emergency use.

Psilocybin, the hallucinogenic substance found in "magic" mushrooms, appears to relieve the symptoms of major depression.

The federal government plans to distribute 300,000 doses of the drug at no cost, but that doesn't mean treatment will be free. Intravenous infusion charges can run more than $1,000.

Most of the federal contracts with companies involved in the crash program to make COVID-19 vaccines haven't been made public. The lack of disclosure raises questions about accountability.

A panel of doctor and scientists raised questions about the expedited regulatory path the Food and Drug Administration is considering for COVID-19 vaccines.

Experimental medicines have the potential to help people with COVID-19 avoid hospitalization. The scarce supply of the treatments would have to be rationed, if regulators OK their use.

More hospitalized patients are surviving than early in the pandemic. Improved treatments make a big difference, but so does flattening the curve to keep hospitals from overfilling, researchers say.

Researchers launched a major study of an experimental Alzheimer's drug this summer. They also learned a lot about how to protect participants who must make frequent visits to a medical center.